Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 398

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys

Open access
Hallal, Pedro C, Hartwig, Fernando P, Horta, Bernardo L, Silveira, Mariângela F, Struchiner, Claudio J, Vidaletti, Luís P, Neumann, Nelson A, Pellanda, Lucia C, Dellagostin, Odir A, Burattini, Marcelo N, Victora, Gabriel D, Menezes, Ana M B, Barros, Fernando C, Barros, Aluísio J D, Victora, Cesar G·2020·The Lancet Global Health

Abstract

BACKGROUND: Population-based data on COVID-19 are essential for guiding policies. There are few such studies, particularly from low or middle-income countries. Brazil is currently a hotspot for COVID-19 globally. We aimed to investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence by city and according to sex, age, ethnicity group, and socioeconomic status, and compare seroprevalence estimates with official statistics on deaths and cases. METHODS: In this repeated cross-sectional study, we did two seroprevalence surveys in 133 sentinel cities in all Brazilian states. We randomly selected households and randomly selected one individual from all household members. We excluded children younger than 1 year. Presence of antibodies against SARS-CoV-2 was assessed using a lateral flow point-of-care test, the WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech, Guangzhou, China), using two drops of blood from finger prick samples. This lateral-flow assay detects IgG and IgM isotypes that are specific to the SARS-CoV-2 receptor binding domain of the spike protein. Participants also answered short questionnaires on sociodemographic information (sex, age, education, ethnicity, household size, and household assets) and compliance with physical distancing measures. FINDINGS: We included 25 025 participants in the first survey (May 14-21) and 31 165 in the second (June 4-7). For the 83 (62%) cities with sample sizes of more than 200 participants in both surveys, the pooled seroprevalence increased from 1·9% (95% CI 1·7-2·1) to 3·1% (2·8-3·4). City-level prevalence ranged from 0% to 25·4% in both surveys. 11 (69%) of 16 cities with prevalence above 2·0% in the first survey were located in a stretch along a 2000 km of the Amazon river in the northern region. In the second survey, we found 34 cities with prevalence above 2·0%, which included the same 11 Amazon cities plus 14 from the northeast region, where prevalence was increasing rapidly. Prevalence levels were lower in the south and centre-west, and intermediate in the southeast, where the highest level was found in Rio de Janeiro (7·5% [4·2-12·2]). In the second survey, prevalence was similar in men and women, but an increased prevalence was observed in participants aged 20-59 years and those living in crowded conditions (4·4% [3·5-5·6] for those living with households with six or more people). Prevalence among Indigenous people was 6·4% (4·1-9·4) compared with 1·4% (1·2-1·7) among White people. Prevalence in the poorest socioeconomic quintile was 3·7% (3·2-4·3) compared with 1·7% (1·4-2·2) in the wealthiest quintile. INTERPRETATION: Antibody prevalence was highly heterogeneous by country region, with rapid initial escalation in Brazil's north and northeast. Prevalence is strongly associated with Indigenous ancestry and low socioeconomic status. These population subgroups are unlikely to be protected if the policy response to the pandemic by the national government continues to downplay scientific evidence. FUNDING: Brazilian Ministry of Health, Instituto Serrapilheira, Brazilian Collective Health Association, and the JBS Fazer o Bem Faz Bem.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2214-109x(20)30387-9

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 7

  1. Barreto, 2020, What is urgent and necessary to inform policies to deal with the COVID-19 pandemic in Brazil?, Revista Brasileira de Epidemiologia, 23
  2. 2020, COVID-19 in Brazil: “So what?”, Lancet, 395
  3. Whitman, 2020, Test performance evaluation of SARS-CoV-2 serological assays, medRxiv
  4. 2020, COVID-19 in Africa: no room for complacency, Lancet, 395
  5. Pereira, 2020, Fases da pandemia em 6 capitais da Amazônia brasileira, ODS Atlas Amazonas, 2, 1
  6. Aleixo, 2020, Along waterways: mobility and evolution of COVID-19 in the state of Amazonas, Confins, 45
  7. Campos, 2017, Differences in mortality between indigenous and non-indigenous persons in Brazil based on the 2010 Population Census, Cad Saude Publica, 33

Cited by

See all 398

Metadata

Authors
Hallal, P. C., Hartwig, F. P., Horta, B. L., Silveira, M. F., Struchiner, C. J., Vidaletti, L. P., Neumann, N. A., Pellanda, L. C., Dellagostin, O. A., Burattini, M. N., Victora, G. D., Menezes, A. M. B., Barros, F. C., Barros, A. J. D., & Victora, C. G.
Venue
The Lancet Global Health
Publisher
Elsevier BV
Published
2020-11
Volume
8
Issue
11
Pages
e1390-e1398
ISSN
2214-109X (ISSN-L)
OpenAlex
W3087050596
Cited by
398
References
23
FWCI
9.93
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Instituto Serrapilheira
  • Associação Brasileira de Saúde Coletiva

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. https://app.cochat.ai/papers/10.1016/s2214-109x(20)30387-9
The paper
Hallal, P. C., Hartwig, F. P., Horta, B. L., Silveira, M. F., Struchiner, C. J., Vidaletti, L. P., Neumann, N. A., Pellanda, L. C., Dellagostin, O. A., Burattini, M. N., Victora, G. D., Menezes, A. M. B., Barros, F. C., Barros, A. J. D., & Victora, C. G. (2020). SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(20)30387-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.